ROSS M MICHELS
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology SENECA, SC NPI 1679740211
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology SC Incyte Corporation All categories
General Payments — all program years on this page
$11,267.14
- Category: General Payments
- Program years: PY2018–2024
- Record count: 168
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $3,046.76 across 53 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,912.82 | 51 |
| Education | $133.94 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $445.94 | 5 |
| Merck Sharp & Dohme Corporation | $274.09 | 4 |
| Acerta Pharma LLC | $257.41 | 5 |
| E.R. Squibb & Sons, L.L.C. | $200.81 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $172.41 | 3 |
| BeiGene USA, Inc. | $157.74 | 2 |
| Rigel Pharmaceuticals, Inc. | $145.68 | 2 |
| Galvanize Therapeutics, Inc | $143.28 | 1 |
| ABBVIE INC. | $124.16 | 1 |
| SpringWorks Therapeutics, Inc. | $121.80 | 1 |
| PFIZER INC. | $116.87 | 5 |
| SOBI, INC | $109.47 | 1 |
| Amgen Inc. | $102.96 | 1 |
| Gilead Sciences, Inc. | $100.16 | 3 |
| CSL Behring | $100.14 | 1 |
| AVEO Pharmaceuticals, Inc. | $96.38 | 1 |
| Janssen Biotech, Inc. | $88.25 | 1 |
| Daiichi Sankyo Inc. | $53.81 | 1 |
| Lilly USA, LLC | $32.56 | 2 |
| Alexion Pharmaceuticals, Inc. | $29.99 | 1 |
| Stemline Therapeutics Inc. | $29.84 | 1 |
| Deciphera Pharmaceuticals Inc. | $29.02 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $26.11 | 1 |
| ARRAY BIOPHARMA INC | $25.62 | 4 |
| EISAI INC. | $24.64 | 1 |
| Celgene Corporation | $22.97 | 1 |
| Genentech USA, Inc. | $14.65 | 1 |
By program year
Records — PY2024 (53)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.